{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:23:50Z","timestamp":1793643830919,"version":"4.5.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Extranodal natural killer\/T-cell lymphoma (NKTL) is an aggressive type of non-Hodgkin lymphoma with dismal outcome. A better understanding of disease biology and key oncogenic process is necessary for the development of targeted therapy. Super-enhancers (SEs) have been shown to drive pivotal oncogenes in various malignancies. However, the landscape of SEs and SE-associated oncogenes remain elusive in NKTL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used Nano-ChIP-seq of the active enhancer marker histone H3 lysine 27 acetylation (H3K27ac) to profile unique SEs NKTL primary tumor samples. Integrative analysis of RNA-seq and survival data further pinned down high value, novel SE oncogenes. We utilized shRNA knockdown, CRISPR-dCas9, luciferase reporter assay, ChIP-PCR to investigate the regulation of transcription factor (TF) on SE oncogenes. Multi-color immunofluorescence (mIF) staining was performed on an independent cohort of clinical samples. Various function experiments were performed to evaluate the effects of TOX2 on the malignancy of NKTL in vitro and in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SE landscape was substantially different in NKTL samples in comparison with normal tonsils. Several SEs at key transcriptional factor (TF) genes, including <jats:italic>TOX2, TBX21(T-bet), EOMES, RUNX2,<\/jats:italic> and <jats:italic>ID2<\/jats:italic>, were identified. We confirmed that TOX2 was aberrantly overexpressed in NKTL relative to normal NK cells and high expression of TOX2 was associated with worse survival. Modulation of TOX2 expression by shRNA, CRISPR-dCas9 interference of SE function impacted on cell proliferation, survival and colony formation ability of NKTL cells. Mechanistically, we found that RUNX3 regulates TOX2 transcription by binding to the active elements of its SE. Silencing TOX2 also impaired tumor formation of NKTL cells in vivo. Metastasis-associated phosphatase PRL-3 has been identified and validated as a key downstream effector of TOX2-mediated oncogenesis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our integrative SE profiling strategy revealed the landscape of SEs, novel targets and insights into molecular pathogenesis of NKTL. The RUNX3-TOX2-SE-TOX2-PRL-3 regulatory pathway may represent a hallmark of NKTL biology. Targeting TOX2 could be a valuable therapeutic intervene for NKTL patients and warrants further study in clinic.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-023-01767-1","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T02:02:43Z","timestamp":1681092163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer\/T Cell Lymphoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Jianbiao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Hui-Min","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze King","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpnaa","family":"Balan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Quan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan Zea","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siok-Bian","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand D.","family":"Jeyasekharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Thye","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Ann Johnny","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon Kiat","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Sanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee-Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"1767_CR1","first-page":"e523","volume":"5","author":"JA van Doesum","year":"2021","unstructured":"van Doesum JA, Niezink AGH, Huls GA, Beijert M, Diepstra A, van Meerten T. Extranodal Natural Killer\/T-cell Lymphoma. Nasal Type: Diagnosis and Treatment Hemasphere. 2021;5:e523.","journal-title":"Nasal Type: Diagnosis and Treatment Hemasphere"},{"key":"1767_CR2","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","volume":"35","author":"H Wang","year":"2021","unstructured":"Wang H, Fu BB, Gale RP, Liang Y. NK-\/T-cell lymphomas. Leukemia. 2021;35:2460\u20138.","journal-title":"Leukemia"},{"key":"1767_CR3","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1182\/blood-2013-01-453233","volume":"121","author":"E Tse","year":"2013","unstructured":"Tse E, Kwong YL. How I treat NK\/T-cell lymphomas Blood. Blood. 2013;121:4997\u20135005.","journal-title":"Blood"},{"key":"1767_CR4","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1038\/s41375-020-1000-0","volume":"34","author":"JQ Lim","year":"2020","unstructured":"Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng RJ, Wong EKY, Cheah DMZ, Chia BKH, Iqbal J, et al. Whole-genome sequencing identifies responders to Pembrolizumab in relapse\/refractory natural-killer\/T cell lymphoma. Leukemia. 2020;34:3413\u20139.","journal-title":"Leukemia"},{"key":"1767_CR5","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","volume":"131","author":"M Yamaguchi","year":"2018","unstructured":"Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type. Blood. 2018;131:2528\u201340.","journal-title":"Blood"},{"key":"1767_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/17474086.2019.1660640","volume":"12","author":"E Tse","year":"2019","unstructured":"Tse E, Au-Yeung R, Kwong YL. Recent advances in the diagnosis and treatment of natural killer\/T-cell lymphomas. Expert Rev Hematol. 2019;12:927\u201335.","journal-title":"Expert Rev Hematol"},{"key":"1767_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","volume":"19","author":"Y Lu","year":"2020","unstructured":"Lu Y, Chan YT, Tan HY, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020;19:79.","journal-title":"Mol Cancer"},{"key":"1767_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/leu.2010.255","volume":"25","author":"J Iqbal","year":"2011","unstructured":"Iqbal J, Weisenburger DD, Chowdhury A, Tsai MY, Srivastava G, Greiner TC, Kucuk C, Deffenbacher K, Vose J, Smith L, et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia. 2011;25:348\u201358.","journal-title":"Leukemia"},{"key":"1767_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","volume":"115","author":"Y Huang","year":"2010","unstructured":"Huang Y, de Reynies A, de Leval L, Ghazi B, Martin-Garcia N, Travert M, Bosq J, Briere J, Petit B, Thomas E, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type. Blood. 2010;115:1226\u201337.","journal-title":"Blood"},{"key":"1767_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/path.2823","volume":"223","author":"SB Ng","year":"2011","unstructured":"Ng SB, Selvarajan V, Huang G, Zhou J, Feldman AL, Law M, Kwong YL, Shimizu N, Kagami Y, Aozasa K, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK\/T cell lymphoma revealed by gene expression profiling. J Pathol. 2011;223:496\u2013510.","journal-title":"J Pathol"},{"issue":"403\u2013419","key":"1767_CR11","first-page":"e406","volume":"37","author":"J Xiong","year":"2020","unstructured":"Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, Zhong HJ, Cheng S, Ou-Yang BS, Hu Y, et al. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell. 2020;37(403\u2013419):e406.","journal-title":"Cancer Cell"},{"key":"1767_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-019-0717-6","volume":"12","author":"N Somasundaram","year":"2019","unstructured":"Somasundaram N, Lim JQ, Ong CK, Lim ST. Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL). J Hematol Oncol. 2019;12:28.","journal-title":"J Hematol Oncol"},{"key":"1767_CR13","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1182\/blood-2017-11-764357","volume":"131","author":"JS Van Arnam","year":"2018","unstructured":"Van Arnam JS, Lim MS, Elenitoba-Johnson KSJ. Novel insights into the pathogenesis of T-cell lymphomas. Blood. 2018;131:2320\u201330.","journal-title":"Blood"},{"key":"1767_CR14","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1182\/blood.2019000381","volume":"134","author":"B Li","year":"2019","unstructured":"Li B, Yan J, Phyu T, Fan S, Chung TH, Mustafa N, Lin B, Wang L, Eichhorn PJA, Goh BC, et al. MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer\/T-cell lymphoma. Blood. 2019;134:2046\u201358.","journal-title":"Blood"},{"key":"1767_CR15","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2016-01-690701","volume":"128","author":"J Yan","year":"2016","unstructured":"Yan J, Li B, Lin B, Lee PT, Chung TH, Tan J, Bi C, Lee XT, Selvarajan V, Ng SB, et al. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer\/T-cell lymphoma. Blood. 2016;128:948\u201358.","journal-title":"Blood"},{"key":"1767_CR16","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","volume":"121","author":"J Yan","year":"2013","unstructured":"Yan J, Ng SB, Tay JL, Lin B, Koh TL, Tan J, Selvarajan V, Liu SC, Bi C, Wang S, et al. EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood. 2013;121:4512\u201320.","journal-title":"Blood"},{"key":"1767_CR17","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1038\/leu.2017.40","volume":"31","author":"V Selvarajan","year":"2017","unstructured":"Selvarajan V, Osato M, Nah GSS, Yan J, Chung TH, Voon DC, Ito Y, Ham MF, Salto-Tellez M, Shimizu N, et al. RUNX3 is oncogenic in natural killer\/T-cell lymphoma and is transcriptionally regulated by MYC. Leukemia. 2017;31:2219\u201327.","journal-title":"Leukemia"},{"key":"1767_CR18","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/leu.2009.91","volume":"23","author":"P Coppo","year":"2009","unstructured":"Coppo P, Gouilleux-Gruart V, Huang Y, Bouhlal H, Bouamar H, Bouchet S, Perrot C, Vieillard V, Dartigues P, Gaulard P, et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK\/T-cell lymphoma. Leukemia. 2009;23:1667\u201378.","journal-title":"Leukemia"},{"key":"1767_CR19","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1038\/ncomms7025","volume":"6","author":"C Kucuk","year":"2015","unstructured":"Kucuk C, Jiang B, Hu X, Zhang W, Chan JK, Xiao W, Lack N, Alkan C, Williams JC, Avery KN, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun. 2015;6:6025.","journal-title":"Nat Commun"},{"key":"1767_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-019-0716-7","volume":"12","author":"S de Mel","year":"2019","unstructured":"de Mel S, Hue SS, Jeyasekharan AD, Chng WJ, Ng SB. Molecular pathogenic pathways in extranodal NK\/T cell lymphoma. J Hematol Oncol. 2019;12:33.","journal-title":"J Hematol Oncol"},{"key":"1767_CR21","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1182\/blood-2011-07-364224","volume":"118","author":"SB Ng","year":"2011","unstructured":"Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B, Bi C, Tan J, Kwong YL, Shimizu N, et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer\/T-cell lymphoma. Blood. 2011;118:4919\u201329.","journal-title":"Blood"},{"key":"1767_CR22","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-14-1216","volume":"21","author":"C Kucuk","year":"2015","unstructured":"Kucuk C, Hu X, Jiang B, Klinkebiel D, Geng H, Gong Q, Bouska A, Iqbal J, Gaulard P, McKeithan TW, Chan WC. Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma. Clin Cancer Res. 2015;21:1699\u2013711.","journal-title":"Clin Cancer Res"},{"key":"1767_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/hon.2362","volume":"35","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Liang L, Li D, Nong L, Liu J, Qu L, Zheng Y, Zhang B, Li T. Hypermethylation of PRDM1\/Blimp-1 promoter in extranodal NK\/T-cell lymphoma, nasal type: an evidence of predominant role in its downregulation. Hematol Oncol. 2017;35:645\u201354.","journal-title":"Hematol Oncol"},{"key":"1767_CR24","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/ajh.26636","volume":"97","author":"JQ Lim","year":"2022","unstructured":"Lim JQ, Huang D, Chan JY, Laurensia Y, Wong EKY, Cheah DMZ, Chia BKH, Chuang WY, Kuo MC, Su YJ, et al. A genomic-augmented multivariate prognostic model for the survival of natural-killer\/T-cell lymphoma patients from an international cohort. Am J Hematol. 2022;97:1159\u201369.","journal-title":"Am J Hematol"},{"key":"1767_CR25","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1182\/blood-2017-11-737379","volume":"131","author":"AS Bhagwat","year":"2018","unstructured":"Bhagwat AS, Lu B, Vakoc CR. Enhancer dysfunction in leukemia. Blood. 2018;131:1795\u2013804.","journal-title":"Blood"},{"key":"1767_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307\u201319.","journal-title":"Cell"},{"key":"1767_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tig.2020.08.015","volume":"37","author":"KM Andre","year":"2021","unstructured":"Andre KM, Sipos EH, Soutourina J. Mediator Roles Going Beyond Transcription. Trends Genet. 2021;37:224\u201334.","journal-title":"Trends Genet"},{"key":"1767_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","volume":"17","author":"B Donati","year":"2018","unstructured":"Donati B, Lorenzini E, Ciarrocchi A. BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer. 2018;17:164.","journal-title":"Mol Cancer"},{"key":"1767_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12943-020-01254-x","volume":"19","author":"CH Yeh","year":"2020","unstructured":"Yeh CH, Bellon M, Wang F, Zhang H, Fu L, Nicot C. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. Mol Cancer. 2020;19:139.","journal-title":"Mol Cancer"},{"key":"1767_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-019-0757-y","volume":"12","author":"Y Jia","year":"2019","unstructured":"Jia Y, Chng WJ, Zhou J. Super-enhancers: critical roles and therapeutic targets in hematologic malignancies. J Hematol Oncol. 2019;12:77.","journal-title":"J Hematol Oncol"},{"key":"1767_CR31","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1182\/blood-2017-06-792184","volume":"130","author":"RWJ Wong","year":"2017","unstructured":"Wong RWJ, Ngoc PCT, Leong WZ, Yam AWY, Zhang T, Asamitsu K, Iida S, Okamoto T, Ueda R, Gray NS, et al. Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. Blood. 2017;130:2326\u201338.","journal-title":"Blood"},{"key":"1767_CR32","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood.2019002639","volume":"135","author":"RWJ Wong","year":"2020","unstructured":"Wong RWJ, Tan TK, Amanda S, Ngoc PCT, Leong WZ, Tan SH, Asamitsu K, Hibi Y, Ueda R, Okamoto T, et al. Feed-forward regulatory loop driven by IRF4 and NF-kappaB in adult T-cell leukemia\/lymphoma. Blood. 2020;135:934\u201347.","journal-title":"Blood"},{"key":"1767_CR33","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1182\/blood-2010-07-294827","volume":"118","author":"J Zhou","year":"2011","unstructured":"Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011;118:2830\u20139.","journal-title":"Blood"},{"key":"1767_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-018-0581-9","volume":"11","author":"J Zhou","year":"2018","unstructured":"Zhou J, Toh SH, Chan ZL, Quah JY, Chooi JY, Tan TZ, Chong PSY, Zeng Q, Chng WJ. A loss-of-function genetic screening reveals synergistic targeting of AKT\/mTOR and WTN\/beta-catenin pathways for treatment of AML with high PRL-3 phosphatase. J Hematol Oncol. 2018;11:36.","journal-title":"J Hematol Oncol"},{"key":"1767_CR35","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.3324\/haematol.2021.280003","volume":"107","author":"CMM Wai","year":"2022","unstructured":"Wai CMM, Chen S, Phyu T, Fan S, Leong SM, Zheng W, Low LCY, Choo SN, Lee CK, Chung TH, et al. Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T\/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica. 2022;107:1864\u201379.","journal-title":"Haematologica"},{"key":"1767_CR36","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.15252\/emmm.201404208","volume":"6","author":"TZ Tan","year":"2014","unstructured":"Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, Thiery JP. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med. 2014;6:1279\u201393.","journal-title":"EMBO Mol Med"},{"key":"1767_CR37","doi-asserted-by":"publisher","first-page":"W214","DOI":"10.1093\/nar\/gkq537","volume":"38","author":"D Warde-Farley","year":"2010","unstructured":"Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38:W214-220.","journal-title":"Nucleic Acids Res"},{"key":"1767_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clim.2018.10.015","volume":"204","author":"I Gordiienko","year":"2019","unstructured":"Gordiienko I, Shlapatska L, Kovalevska L, Sidorenko SP. SLAMF1\/CD150 in hematologic malignancies: Silent marker or active player? Clin Immunol. 2019;204:14\u201322.","journal-title":"Clin Immunol"},{"key":"1767_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-981-10-3233-2_9","volume":"962","author":"CQ Wang","year":"2017","unstructured":"Wang CQ, Mok MM, Yokomizo T, Tergaonkar V, Osato M. Runx Family Genes in Tissue Stem Cell Dynamics. Adv Exp Med Biol. 2017;962:117\u201338.","journal-title":"Adv Exp Med Biol"},{"key":"1767_CR40","doi-asserted-by":"crossref","unstructured":"Mevel R, Draper JE, Lie ALM, Kouskoff V, Lacaud G: RUNX transcription factors: orchestrators of development. Development 2019, 146.","DOI":"10.1242\/dev.148296"},{"key":"1767_CR41","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/sj.onc.1208404","volume":"24","author":"LC Spender","year":"2005","unstructured":"Spender LC, Whiteman HJ, Karstegl CE, Farrell PJ. Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells. Oncogene. 2005;24:1873\u201381.","journal-title":"Oncogene"},{"key":"1767_CR42","doi-asserted-by":"publisher","first-page":"6909","DOI":"10.1128\/JVI.00216-09","volume":"83","author":"G Brady","year":"2009","unstructured":"Brady G, Whiteman HJ, Spender LC, Farrell PJ. Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation. J Virol. 2009;83:6909\u201316.","journal-title":"J Virol"},{"key":"1767_CR43","doi-asserted-by":"crossref","unstructured":"Wang J, Zhuang J, Iyer S, Lin XY, Greven MC, Kim BH, Moore J, Pierce BG, Dong X, Virgil D, et al: Factorbook.org: a Wiki-based database for transcription factor-binding data generated by the ENCODE consortium. Nucleic Acids Res 2013, 41:D171\u2013176.","DOI":"10.1093\/nar\/gks1221"},{"key":"1767_CR44","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.tibs.2012.09.003","volume":"37","author":"CS Malarkey","year":"2012","unstructured":"Malarkey CS, Churchill ME. The high mobility group box: the ultimate utility player of a cell. Trends Biochem Sci. 2012;37:553\u201362.","journal-title":"Trends Biochem Sci"},{"key":"1767_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2164-4-13","volume":"4","author":"E O'Flaherty","year":"2003","unstructured":"O\u2019Flaherty E, Kaye J. TOX defines a conserved subfamily of HMG-box proteins. BMC Genomics. 2003;4:13.","journal-title":"BMC Genomics"},{"key":"1767_CR46","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1158\/2159-8290.CD-17-0267","volume":"7","author":"R Lobbardi","year":"2017","unstructured":"Lobbardi R, Pinder J, Martinez-Pastor B, Theodorou M, Blackburn JS, Abraham BJ, Namiki Y, Mansour M, Abdelfattah NS, Molodtsov A, et al. TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2017;7:1336\u201353.","journal-title":"Cancer Discov"},{"key":"1767_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.740642","volume":"11","author":"C Liang","year":"2021","unstructured":"Liang C, Zhao Y, Chen C, Huang S, Deng T, Zeng X, Tan J, Zha X, Chen S, Li Y. Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia. Front Oncol. 2021;11: 740642.","journal-title":"Front Oncol"},{"key":"1767_CR48","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2014-06-582965","volume":"124","author":"QP Vong","year":"2014","unstructured":"Vong QP, Leung WH, Houston J, Li Y, Rooney B, Holladay M, Oostendorp RA, Leung W. TOX2 regulates human natural killer cell development by controlling T-BET expression. Blood. 2014;124:3905\u201313.","journal-title":"Blood"},{"issue":"826\u2013839","key":"1767_CR49","first-page":"e825","volume":"51","author":"W Xu","year":"2019","unstructured":"Xu W, Zhao X, Wang X, Feng H, Gou M, Jin W, Wang X, Liu X, Dong C. The Transcription Factor Tox2 Drives T Follicular Helper Cell Development via Regulating Chromatin Accessibility. Immunity. 2019;51(826\u2013839):e825.","journal-title":"Immunity"},{"key":"1767_CR50","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/jcb.22913","volume":"111","author":"AQ Al-Aidaroos","year":"2010","unstructured":"Al-Aidaroos AQ, Zeng Q. PRL-3 phosphatase and cancer metastasis. J Cell Biochem. 2010;111:1087\u201398.","journal-title":"J Cell Biochem"},{"key":"1767_CR51","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41388-018-0526-3","volume":"38","author":"PSY Chong","year":"2019","unstructured":"Chong PSY, Zhou J, Chooi JY, Chan ZL, Toh SHM, Tan TZ, Wee S, Gunaratne J, Zeng Q, Chng WJ. Non-canonical activation of beta-catenin by PRL-3 phosphatase in acute myeloid leukemia. Oncogene. 2019;38:1508\u201319.","journal-title":"Oncogene"},{"key":"1767_CR52","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1182\/blood-2007-07-101139","volume":"111","author":"UM Fagerli","year":"2008","unstructured":"Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 2008;111:806\u201315.","journal-title":"Blood"},{"key":"1767_CR53","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41375-020-0937-3","volume":"35","author":"EG Garcia","year":"2021","unstructured":"Garcia EG, Veloso A, Oliveira ML, Allen JR, Loontiens S, Brunson D, Do D, Yan C, Morris R, Iyer S, et al. PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. Leukemia. 2021;35:679\u201390.","journal-title":"Leukemia"},{"key":"1767_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ccr.2010.04.028","volume":"18","author":"H Wang","year":"2010","unstructured":"Wang H, Vardy LA, Tan CP, Loo JM, Guo K, Li J, Lim SG, Zhou J, Chng WJ, Ng SB, et al. PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell. 2010;18:52\u201362.","journal-title":"Cancer Cell"},{"key":"1767_CR55","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1476-4598-11-72","volume":"11","author":"J Zhou","year":"2012","unstructured":"Zhou J, Cheong LL, Liu SC, Chong PS, Mahara S, Bi C, Ong KO, Zeng Q, Chng WJ. The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia. Mol Cancer. 2012;11:72.","journal-title":"Mol Cancer"},{"key":"1767_CR56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1476-4598-8-46","volume":"8","author":"DG Mollevi","year":"2009","unstructured":"Mollevi DG, Aytes A, Berdiel M, Padulles L, Martinez-Iniesta M, Sanjuan X, Salazar R, Villanueva A. PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts. Mol Cancer. 2009;8:46.","journal-title":"Mol Cancer"},{"key":"1767_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1476-4598-8-110","volume":"8","author":"L Peng","year":"2009","unstructured":"Peng L, Xing X, Li W, Qu L, Meng L, Lian S, Jiang B, Wu J, Shou C. PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1\/2 and-MMP2 signaling. Mol Cancer. 2009;8:110.","journal-title":"Mol Cancer"},{"key":"1767_CR58","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12967-021-03085-w","volume":"19","author":"E Capone","year":"2021","unstructured":"Capone E, Iacobelli S, Sala G. Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target. J Transl Med. 2021;19:405.","journal-title":"J Transl Med"},{"key":"1767_CR59","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1182\/blood.V96.9.3282","volume":"96","author":"B Fornarini","year":"2000","unstructured":"Fornarini B, D\u2019Ambrosio C, Natoli C, Tinari N, Silingardi V, Iacobelli S. Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood. 2000;96:3282\u20135.","journal-title":"Blood"},{"key":"1767_CR60","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-16-0574","volume":"16","author":"JK Woo","year":"2017","unstructured":"Woo JK, Jang JE, Kang JH, Seong JK, Yoon YS, Kim HC, Lee SJ, Oh SH. Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K\/Akt Pathway in Lung Cancer Cell Line. Mol Cancer Ther. 2017;16:1355\u201365.","journal-title":"Mol Cancer Ther"},{"key":"1767_CR61","first-page":"5","volume":"29","author":"S L'Esperance","year":"2006","unstructured":"L\u2019Esperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Tetu B, Bachvarov D. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol. 2006;29:5\u201324.","journal-title":"Int J Oncol"},{"key":"1767_CR62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinbiochem.2018.07.003","volume":"59","author":"MA Icer","year":"2018","unstructured":"Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018;59:17\u201324.","journal-title":"Clin Biochem"},{"key":"1767_CR63","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1634\/stemcells.2008-0370","volume":"26","author":"JW Chung","year":"2008","unstructured":"Chung JW, Kim MS, Piao ZH, Jeong M, Yoon SR, Shin N, Kim SY, Hwang ES, Yang Y, Lee YH, et al. Osteopontin promotes the development of natural killer cells from hematopoietic stem cells. Stem Cells. 2008;26:2114\u201323.","journal-title":"Stem Cells"},{"key":"1767_CR64","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1073\/pnas.1423011112","volume":"112","author":"JW Leavenworth","year":"2015","unstructured":"Leavenworth JW, Verbinnen B, Wang Q, Shen E, Cantor H. Intracellular osteopontin regulates homeostasis and function of natural killer cells. Proc Natl Acad Sci U S A. 2015;112:494\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1767_CR65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbrc.2022.02.022","volume":"600","author":"J Zhou","year":"2022","unstructured":"Zhou J, Chen X, Zhou P, Sun X, Chen Y, Li M, Chu Y, Zhou J, Hu X, Luo Y, et al. Osteopontin is required for the maintenance of leukemia stem cells in acute myeloid leukemia. Biochem Biophys Res Commun. 2022;600:29\u201334.","journal-title":"Biochem Biophys Res Commun"},{"key":"1767_CR66","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2014.01.005","volume":"14","author":"A Pietras","year":"2014","unstructured":"Pietras A, Katz AM, Ekstrom EJ, Wee B, Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT, Holland EC. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell. 2014;14:357\u201369.","journal-title":"Cell Stem Cell"},{"key":"1767_CR67","doi-asserted-by":"crossref","unstructured":"Qian J, LeSavage BL, Hubka KM, Ma C, Natarajan S, Eggold JT, Xiao Y, Fuh KC, Krishnan V, Enejder A, et al: Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling. J Clin Invest 2021, 131.","DOI":"10.1172\/JCI146186"},{"key":"1767_CR68","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1038\/s41388-020-01452-3","volume":"39","author":"Q Sun","year":"2020","unstructured":"Sun Q, Ye Z, Qin Y, Fan G, Ji S, Zhuo Q, Xu W, Liu W, Hu Q, Liu M, et al. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2\/ITGB7\/FAK axis. Oncogene. 2020;39:6572\u201388.","journal-title":"Oncogene"},{"key":"1767_CR69","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3324\/haematol.2016.151555","volume":"102","author":"F Zhang","year":"2017","unstructured":"Zhang F, Liu X, Chen C, Zhu J, Yu Z, Xie J, Xie L, Bai H, Zhang Y, Fang X, et al. CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2\/p27(kip1) signaling. Haematologica. 2017;102:707\u201318.","journal-title":"Haematologica"},{"key":"1767_CR70","doi-asserted-by":"crossref","unstructured":"Matsunuma R, Chan DW, Kim BJ, Singh P, Han A, Saltzman AB, Cheng C, Lei JT, Wang J, Roberto da Silva L, et al: DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 2018, 115:E11978-E11987.","DOI":"10.1073\/pnas.1810598115"},{"key":"1767_CR71","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41419-018-1030-y","volume":"9","author":"C Li","year":"2018","unstructured":"Li C, Liu X, Liu Y, Liu X, Wang R, Liao J, Wu S, Fan J, Peng Z, Li B, Wang Z. Keratin 80 promotes migration and invasion of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway. Cell Death Dis. 2018;9:1009.","journal-title":"Cell Death Dis"},{"key":"1767_CR72","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/onc.2010.456","volume":"30","author":"V Karantza","year":"2011","unstructured":"Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2011;30:127\u201338.","journal-title":"Oncogene"},{"key":"1767_CR73","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1128\/JVI.75.8.3537-3546.2001","volume":"75","author":"LC Spender","year":"2001","unstructured":"Spender LC, Cornish GH, Rowland B, Kempkes B, Farrell PJ. Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J Virol. 2001;75:3537\u201346.","journal-title":"J Virol"},{"key":"1767_CR74","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.chom.2014.12.013","volume":"17","author":"H Zhou","year":"2015","unstructured":"Zhou H, Schmidt SC, Jiang S, Willox B, Bernhardt K, Liang J, Johannsen EC, Kharchenko P, Gewurz BE, Kieff E, Zhao B. Epstein-Barr virus oncoprotein super-enhancers control B cell growth. Cell Host Microbe. 2015;17:205\u201316.","journal-title":"Cell Host Microbe"},{"key":"1767_CR75","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1093\/nar\/gkw085","volume":"44","author":"A Gunnell","year":"2016","unstructured":"Gunnell A, Webb HM, Wood CD, McClellan MJ, Wichaidit B, Kempkes B, Jenner RG, Osborne C, Farrell PJ, West MJ. RUNX super-enhancer control through the Notch pathway by Epstein-Barr virus transcription factors regulates B cell growth. Nucleic Acids Res. 2016;44:4636\u201350.","journal-title":"Nucleic Acids Res"},{"key":"1767_CR76","doi-asserted-by":"publisher","first-page":"145421","DOI":"10.1016\/j.gene.2021.145421","volume":"774","author":"H Hosoi","year":"2021","unstructured":"Hosoi H, Niibori-Nambu A, Nah GSS, Bahirvani AG, Mok MMH, Sanda T, Kumar AP, Tenen DG, Ito Y, Sonoki T, Osato M. Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines. Gene. 2021;774:145421.","journal-title":"Gene"},{"key":"1767_CR77","doi-asserted-by":"crossref","unstructured":"Deng R, Huang JH, Wang Y, Zhou LH, Wang ZF, Hu BX, Chen YH, Yang D, Mai J, Li ZL, et al: Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma. Mol Cancer 2020, 19:122.","DOI":"10.1186\/s12943-020-01236-z"},{"key":"1767_CR78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.exphem.2021.02.005","volume":"97","author":"T Yokomizo-Nakano","year":"2021","unstructured":"Yokomizo-Nakano T, Sashida G. Two faces of RUNX3 in myeloid transformation. Exp Hematol. 2021;97:14\u201320.","journal-title":"Exp Hematol"},{"key":"1767_CR79","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3389\/fphar.2020.00820","volume":"11","author":"H Shi","year":"2020","unstructured":"Shi H, Li C, Feng W, Yue J, Song J, Peng A, Wang H. BCL11A Is Oncogenic and Predicts Poor Outcomes in Natural Killer\/T-Cell Lymphoma. Front Pharmacol. 2020;11:820.","journal-title":"Front Pharmacol"},{"key":"1767_CR80","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.4081\/hr.2020.8368","volume":"12","author":"Y Yamashita","year":"2020","unstructured":"Yamashita Y, Hori Y, Kosako H, Oiwa T, Warigaya K, Mushino T, Murata S, Fujimoto M, Nishikawa A, Murata SI, et al. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with RUNX3 overexpression. Hematol Rep. 2020;12:8368.","journal-title":"Hematol Rep"},{"key":"1767_CR81","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21:181\u2013200.","journal-title":"Nat Rev Drug Discov"},{"key":"1767_CR82","doi-asserted-by":"publisher","first-page":"e87607","DOI":"10.1172\/jci.insight.87607","volume":"1","author":"M Thura","year":"2016","unstructured":"Thura M, Al-Aidaroos AQO, Yong WP, Kono K, Gupta A, Lin YB, Mimura K, Thiery JP, Goh BC, Tan P, et al. PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight. 2016;1:e87607.","journal-title":"JCI Insight"},{"key":"1767_CR83","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1038\/s41467-019-10127-x","volume":"10","author":"M Thura","year":"2019","unstructured":"Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, et al. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nat Commun. 2019;10:2484.","journal-title":"Nat Commun"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01767-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01767-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01767-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T03:15:10Z","timestamp":1681096510000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01767-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1767"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01767-1","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study with patient tumor samples was approved by the ethics review board of National Cancer Centre Singapore and National University Health System and conducted in accordance with the Declaration of Helsinki. Informed consents were obtained. Animal experiments were approved by the National University of Singapore Institutional Animal Care and Use Committee (IACUC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give consent for the publication of manuscript in <i>Molecular Cancer<\/i>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}